American Cyanamid Company

Joseph M Backer

Peter Bohlen

Phaik-Eng Sum

Michael R Ostrander

The invention relates to a method for inhibiting angiogenesis and proliferation of endothelial cells by administering an inhibitory amount of 7-�substituted amino!-9-�(substituted glycyl)amido!-6-demethyl-6-deoxytetracycline of Formula I: ##STR1## wherein R, R.sub.2, R.sub.3, and W are as defined in the specification. The invention also relates to a method for inhibiting proliferation of tumor cells and tumor growth by administering an inhibitory amount of a compound of Formula I in combination with a chemotherapeutic agent or radiation therapy. The invention also relates to compositions containing an effective inhibitory amount of a compound of Formula I in a pharmaceutically acceptable carrier.

Methods for inhibiting proliferation of tumor cells and tumor growth

The invention relates to a method for inhibiting angiogenesis and proliferation of endothelial cells by administering an inhibitory amount of a 7-�substituted amino!-9-�(substituted glycyl)amido!-6-demethyl-6-deoxytetracycline of Formula I: ##STR1## wherein R, R.sub.2, R.sub.3, and W are as defined in the specification. The invention also relates to a method for inhibiting proliferation of tumor cells and tumor growth by administering an inhibitory amount of a compound of Formula I in combination with a chemotherapeutic agent or radiation therapy. The invention also relates to compositions containing an effective inhibitory amount of a compound of Formula I in a pharmaceutically acceptable carrier.

Methods for inhibiting angiogenesis, proliferation of endothelial or

The invention relates to a method for inhibiting angiogenesis and proliferation of endothelial cells by administering an inhibitory amount of a 7-halogen-9-[hydrogen or [(substituted glycyl)amido]]-6-demethyl-6-deoxytetracycline of Formula I: ##STR1## wherein X and W are as defined in the specification. The invention also relates to a method for inhibiting proliferation of tumor cells and tumor growth by administering an inhibitory amount of a compound of Formula I in combination with a chemotherapeutic agent or radiation therapy. The invention also relates to compositions containing an effective inhibitory amount of a compound of Formula I in a pharmaceutically acceptable carrier.

Methods for inhibiting angiogenesis proliferation of endothelial or

The invention relates to a method for inhibiting angiogenesis and proliferation of endothelial cells by administering an inhibitory amount of a 7-(hydrogen or di (C.sub.1 -C.sub.4)alkylamino)-8-halogen-9-(substituted)-6-demethyl-6-deoxytetracycl ine of Formula I: ##STR1## wherein R, X and W are as defined in the specification. The invention also relates to a method for inhibiting proliferation of tumor cells and tumor growth by administering an inhibitory amount of a compound of Formula I in combination with a chemotherapeutic agent or radiation therapy. The invention also relates to compositions containing an effective inhibitory amount of a compound of Formula I in a pharmaceutically acceptable carrier.

Method for inhibiting angiogenesis, proliferation of endothelial or

The invention relates to a method for inhibiting angiogenesis and proliferation of endothelial cells by administering an inhibitory amount of a 9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracycline of Formula I: ##STR1## wherein W, R.sub.2 and R.sub.3 are as defined in the specification. The invention also relates to a method for inhibiting proliferation of tumor cells and tumor growth by administering an inhibitory amount of a compound of Formula I in combination with a chemotherapeutic agent or radiation therapy. The invention also relates to compositions containing an effective inhibitory amount of a compound of Formula I in a pharmaceutically acceptable carrier.

The disclosure relates to a method of inhibiting the infectivity of a virus, the virus being characterized by the presence of a heparin-binding protein, which comprises contacting the cellular receptor for the virus or the receptor-binding protein of the virus with an effective amount of a pharmaceutical composition containing the HBNF protein, the MK protein or a combination thereof in a sufficient amount to inhibit the infectivity of the virus. Also, this disclosure concerns a method of preventing or treating a viral infection in a subject, the virus being characterized by the presence of a heparin-binding protein, which comprises administering to the subject an effective amount of a pharmaceutical composition containing HBNF, MK or a combination thereof in a sufficient amount to prevent or treat the viral infection in the subject. Further, the disclosure describes a new composition comprising a combination of the HBNF and MK proteins. Both HBNF and MK possess heparin-binding activity, displace bFGF from high affinity receptors and inhibit growth of endothelial cells.

Growing community of inventors

Tenafly, NJ, United States of America

Joseph M Backer